Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice

OBJECTIVE Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby hA/hIAPP causes diabetes in hemizygous hA/hIAPP-transgenic mice. RESEARCH DESIGN AND METHODS We chronically treated hemizygous hA/hIAPP transgenic mice with oral tetracycline to determine its effects on rates of diabetes initiation, progression, and survival. RESULTS Homozygous mice developed severe spontaneous diabetes due to islet β-cell loss. Hemizygous transgenic animals also developed spontaneous diabetes, although severity was less and progression rates slower. Pathogenesis was characterized by initial islet β-cell dysfunction followed by progressive β-cell loss. Islet amyloid was absent from hemizygous animals with early-onset diabetes and correlated positively with longevity. Some long-lived nondiabetic hemizygous animals also had large islet-amyloid areas, showing that amyloid itself was not intrinsically cytotoxic. Administration of tetracycline dose-dependently ameliorated hyperglycemia and polydipsia, delayed rates of diabetes initiation and progression, and increased longevity compared with water-treated controls. CONCLUSIONS This is the first report to show that treating hA/hIAPP transgenic mice with a modifier of hA/hIAPP misfolding can ameliorate their diabetic phenotype. Fibrillar amyloid was neither necessary nor sufficient to cause diabetes and indeed was positively correlated with longevity therein, whereas early- to mid-stage diabetes was associated with islet β-cell dysfunction followed by β-cell loss. Interventions capable of suppressing misfolding in soluble hA/hIAPP oligomers rather than mature fibrils may have potential for treating or preventing type 2 diabetes.

[1]  A. Riggs,et al.  Genomic sequencing. , 1993, Methods in molecular biology.

[2]  S. Kahn,et al.  - Cell Glucokinase Deficiency and Hyperglycemia Are Associated With Reduced Islet Amyloid Deposition in a Mouse Model of Type 2 Diabetes , 2000 .

[3]  S. Kahn,et al.  Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes , 2000, Diabetologia.

[4]  W. Soeller,et al.  Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. , 2002, Diabetes.

[5]  Eugene,et al.  THE RELATION OF DIABETES ~ELLITUS TO LESIONS OF THE PANCREAS. HYALINE DEGENERATION OF THE ISLANDS OF LANGERHANS , 2001 .

[6]  W. Soeller,et al.  Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. , 2003, Diabetes.

[7]  S. Gordon,et al.  Recognizing death: the phagocytosis of apoptotic cells. , 1998, Trends in cell biology.

[8]  G. Bates,et al.  Minocycline and doxycycline are not beneficial in a model of Huntington's disease , 2003, Annals of neurology.

[9]  M. Dragunow,et al.  Fibrillogenic Amylin Evokes Islet β-Cell Apoptosis through Linked Activation of a Caspase Cascade and JNK1* , 2003, Journal of Biological Chemistry.

[10]  D. A. Trainor,et al.  Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. , 1996, Clinical chemistry.

[11]  D. W. Hayden,et al.  Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Harrison,et al.  The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. , 1999, Diabetes.

[13]  J. Thijssen,et al.  Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model , 1999, Diabetologia.

[14]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[15]  J. Kistler,et al.  The aggregation potential of human amylin determines its cytotoxicity towards islet β‐cells , 2006, The FEBS journal.

[16]  W. Soeller,et al.  Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Opie.  THE RELATION OE DIABETES MELLITUS TO LESIONS OF THE PANCREAS. HYALINE DEGENERATION OF THE ISLANDS OE LANGERHANS , 1901, The Journal of experimental medicine.

[18]  S. Kahn,et al.  beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. , 2000, Diabetes.

[19]  G. Forloni,et al.  Anti‐amyloidogenic activity of tetracyclines: studies in vitro , 2001, FEBS letters.

[20]  M. Dragunow,et al.  Increased Expression and Activation of c-Jun Contributes to Human Amylin-induced Apoptosis in Pancreatic Islet β-Cells , 2002 .

[21]  G. Cooper,et al.  Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. , 2003, The Biochemical journal.

[22]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[23]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[24]  J. Chan,et al.  Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes. , 2003, Diabetes.

[25]  P. Fraser,et al.  Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. , 2002, Journal of molecular biology.

[26]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Butler,et al.  Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. , 2008, Endocrine reviews.

[28]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[29]  M. Carty,et al.  Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. , 2004, Diabetes.

[30]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[31]  B. Ahrén,et al.  Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. , 1998, Biochemical and biophysical research communications.

[32]  M. Saraiva,et al.  4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Cooper,et al.  Induction of apoptosis by human amylin in RINm5F islet β‐cells is associated with enhanced expression of p53 and p21WAF1/CIP1 , 1999, FEBS letters.

[35]  G. Forloni,et al.  Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. , 2000, Journal of molecular biology.

[36]  G. Cooper,et al.  Fas-Associated Death Receptor Signaling Evoked by Human Amylin in Islet β-Cells , 2008, Diabetes.

[37]  M. Blankenstein,et al.  Biologically active human islet amyloid polypeptide/amylin in transgenic mice. , 1997, European journal of endocrinology.

[38]  M. Dragunow,et al.  Activation of activating transcription factor 2 by p38 MAP kinase during apoptosis induced by human amylin in cultured pancreatic β‐cells , 2006, The FEBS journal.

[39]  M. Carty,et al.  Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. , 1998, Diabetes.

[40]  U Aebi,et al.  Amyloid fibril formation from full-length and fragments of amylin. , 2000, Journal of structural biology.

[41]  M. Sousa,et al.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.